Companies: 10,795·Total market cap: $144.5T
Biohaven Ltd.

Biohaven Ltd.

BHVNNYSEHealthcare● Active
$11.23
+$0.43(+3.94%)
Market Cap$1.2B
P/E Ratio
52W High$18.566
52W Low$7.48

Biohaven Ltd. (BHVN) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

bhvn · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Biohaven Ltd. (BHVN) measures how much investors pay for each dollar of the company's trailing earnings. BHVN's current PE ratio of N/A is calculated by dividing its stock price of $11.22 by its TTM earnings per share of -$4.39.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-2.44
Based on 11 analysts
EPS (TTM)
-$4.39
TTM · diluted EPS
PEG Ratio
-0.05
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biohaven Ltd. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2017 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Biohaven Ltd.
Biohaven Ltd.You
BHVN
$1.2BN/A-$4.39
AbCellera Biologics Inc.
AbCellera Biologics Inc.
ABCL
$1.7BN/A-$0.49
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
CLDX
$1.9BN/A-$3.89
Immunocore Holdings plc
Immunocore Holdings plc
IMCR
$1.4BN/A-$0.52
Immunome, Inc.
Immunome, Inc.
IMNM
$1.8BN/A-$2.43
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc.
NTLA
$1.5BN/A-$3.81
Pharvaris N.V.
Pharvaris N.V.
PHVS
$2.2BN/A-$2.97

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 9 of 9 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-6.86
2024-12-31
FY2024
$-9.28
2023-12-31
FY2023
$-5.73
2022-12-31
FY2022
$-12.75
2021-12-31
FY2021
$-5.97
2020-12-31
FY2020
$-3.31
2019-12-31
FY2019
$-10.91
2018-12-31
FY2018
$0.00
2017-12-31
FY2017
$0.00

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Biohaven Ltd. (BHVN) measures how much investors pay for each dollar of the company's trailing earnings. BHVN's current PE ratio of N/A is calculated by dividing its stock price of $11.22 by its TTM earnings per share of -$4.39.

PE Ratio = Stock Price ÷ EPS (TTM)
= $11.22 ÷ -$4.39 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

BHVN pe ratio · 6 questions

BHVN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $11.22 and TTM EPS of -$4.39. Data sourced from Financial Modeling Prep via BHVN's SEC 10-K and 10-Q filings.

BHVN PE ratioWhat is BHVN PE ratioCurrent PE ratio of BHVNBHVN PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biohaven Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08